ALX-1393

ALX-1393 is a drug that acts as a selective antagonist for the glycine transporter 1 (GlyT1). It has been researched for its potential use in the treatment of schizophrenia and cognitive disorders.

Pharmacology

ALX-1393 is a potent and selective GlyT1 antagonist. It inhibits the reuptake of glycine, an amino acid that acts as an inhibitory neurotransmitter in the central nervous system. By blocking the reuptake of glycine, ALX-1393 increases the concentration of glycine in the synaptic cleft, which can enhance the function of NMDA receptors and potentially improve cognitive function.

Clinical significance

Research has suggested that GlyT1 antagonists like ALX-1393 may have therapeutic potential in the treatment of schizophrenia and cognitive disorders. These disorders are thought to be associated with hypofunction of NMDA receptors, and increasing the availability of glycine could help to counteract this.

See also

• Glycine transporter 1
• NMDA receptor
• Schizophrenia
• Cognitive disorders

References

ALX-1393 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski